Acquisition Advantage The LipiFlow and LipiScan assets were acquired by Bausch Health in 2023, creating a pathway to scale through Bausch's global ophthalmology sales network and service footprint. This presents an opportunity to rapidly expand adoption across clinics, ambulatory centers, and hospitals, including international markets.

Recurring Revenue LipiFlow Activator II disposables enable a recurring consumables revenue model alongside potential bundled service contracts and training. This supports predictable revenue streams and higher lifetime value from eye care customers.

Channel Partnerships With a lean internal team, strategic distributor and reseller partnerships can extend reach to small and mid-size ophthalmology practices, ASCs, and eye care chains. Consider co-marketing, sales enablement, and training programs to accelerate adoption.

Integrated Imaging The combined portfolio—LipiView II, LipiScan with Dynamic Meibomian Imaging, and Korb Evaluator—offers an end-to-end MGD evaluation and treatment solution. This creates cross-sell opportunities to clinics seeking a single integrated diagnostic and therapeutic platform.

Evidence Maturation FDA clearance for LipiFlow and multicenter clinical studies underpin safety and efficacy, enabling payer discussions and reimbursement strategy. Leverage these data to build ROI-focused proposals for hospitals and ophthalmology practices.